NASDAQ · PRME

Prime Medicine, Inc.

Healthcare · Biotechnology

$4.45▼ 5.83% ($0.27)today

As of 12:42 PM ET

52-week

$2.67$5.91

Market cap

$806.22M

P/E

N/M

EPS (TTM)

-$1.06

Next earnings

Nov 6, 2026

Valuation

Earnings yield

No estimate

Earnings yield isn't available here

Trailing four-quarter earnings were negative, so earnings yield is not meaningful (N/M).

USD · TTM earnings ending Jun 30, 2026 · Price used $4.45 · Price Nov 2, 5:42 PM UTC

Your edits update the card above as you go.

Earnings yield · Maximum entry price

Unavailable

Projected annual return:: Unavailable
Current earnings yield:: Unavailable
10-year Treasury benchmark:: 4.91%

Entry price is a return-based threshold, not an estimate of value.

Trailing four-quarter earnings were negative, so earnings yield is not meaningful (N/M).

USD · TTM earnings ending 2026-06-30

Estimate an entry price from future earnings and your required return. Growth and the exit P/E change the forecast; current earnings yield uses only EPS and the price used.

Earnings per sharePer share · USD

Annual EPS growth percent

Target price-to-earnings multiple

Holding period in years

Required annual return percent

Trailing four-quarter earnings were negative. Enter a positive EPS override, an exit P/E and an EPS growth assumption to calculate a forecast.

EPS basis: trailing four-quarter earnings were negative, so there is no reported EPS to use. Current earnings yield: N/M. Dividends are excluded from projected annual return.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: -2.44%Revenue (TTM): -17.9%FCF (TTM): -46.59%

What changed

The stock fell 2.44% over the last year. Revenue declined 17.9% over the trailing twelve months. Operating margin moved from -4,116.57% to -4,824.94%. Free cash flow declined 46.59% over the trailing twelve months.

What the market seems to be pricing

The stock has moved lower against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

Operating margin currently stands at -4,824.94%. A decisive move in revenue — currently down 17.9% — would be the clearest signal to resolve the ambiguity.

Return analysis

Company profile

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology.

CEOAllan Reine

SectorHealthcare

IndustryBiotechnology

Employees146

IPO dateOct 20, 2022

https://www.primemedicine.com

Market multiples

Forward P/E—

EV/EBITDA (FY2025 year-end)-2.91

Enterprise value (FY2025 year-end)$569.59M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth (Q2 FY26 YoY)3.5%

Gross margin (FY2025)-58.05%▼158.1ppvs FY2024

Operating margin (FY2025)-4,498.06%▲2289.3ppvs FY2024

ROE (TTM to Jun 2026)N/A

Analyst consensus

RatingBuy

Target price$7.50▲68.73%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Actuals vs estimates by quarter, or any quarter against the same one a year earlier.

Next report

Nov 6, 2026

Q3 FY26 · EPS est -$0.24 · Revenue est $1.3M

Q2 FY26

Reported Aug 6, 2026 · Latest

HoverTap a quarter to inspect

Actual

-$0.24

Beat by 6.7%

Estimate

-$0.26

Street consensus

Year over year

n/m

vs Q2 FY25 · -$0.41

Vs prior quarter

n/m

vs Q1 FY26 · -$0.28

Price range $2.70-$3.96 · daily closes Apr 1-Jun 30

2 beats · 2 misses in the last 4 quarters

ActualEstimateBeatMissIn lineSame quarter last year

Institutional Sentiment

Prime Medicine, Inc. · PRME

From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.

NASDAQ · PRME

Prime Medicine, Inc.

Healthcare · Biotechnology

$4.45▼ 5.83% ($0.27)today

As of 12:42 PM ET

52-week

$2.67$5.91

Market cap

$806.22M

P/E

N/M

EPS (TTM)

-$1.06

Next earnings

Nov 6, 2026

Valuation

Earnings yield

No estimate

Earnings yield isn't available here

Trailing four-quarter earnings were negative, so earnings yield is not meaningful (N/M).

USD · TTM earnings ending Jun 30, 2026 · Price used $4.45 · Price Nov 2, 5:42 PM UTC

Your edits update the card above as you go.

Earnings yield · Maximum entry price

Unavailable

Projected annual return:: Unavailable
Current earnings yield:: Unavailable
10-year Treasury benchmark:: 4.91%

Entry price is a return-based threshold, not an estimate of value.

Trailing four-quarter earnings were negative, so earnings yield is not meaningful (N/M).

USD · TTM earnings ending 2026-06-30

Estimate an entry price from future earnings and your required return. Growth and the exit P/E change the forecast; current earnings yield uses only EPS and the price used.

Earnings per sharePer share · USD

Annual EPS growth percent

Target price-to-earnings multiple

Holding period in years

Required annual return percent

Trailing four-quarter earnings were negative. Enter a positive EPS override, an exit P/E and an EPS growth assumption to calculate a forecast.

EPS basis: trailing four-quarter earnings were negative, so there is no reported EPS to use. Current earnings yield: N/M. Dividends are excluded from projected annual return.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: -2.44%Revenue (TTM): -17.9%FCF (TTM): -46.59%

What changed

What the market seems to be pricing

What would invalidate this read

Operating margin currently stands at -4,824.94%. A decisive move in revenue — currently down 17.9% — would be the clearest signal to resolve the ambiguity.

Return analysis

Company profile

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology.

CEOAllan Reine

SectorHealthcare

IndustryBiotechnology

Employees146

IPO dateOct 20, 2022

https://www.primemedicine.com

Market multiples

Forward P/E—

EV/EBITDA (FY2025 year-end)-2.91

Enterprise value (FY2025 year-end)$569.59M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth (Q2 FY26 YoY)3.5%

Gross margin (FY2025)-58.05%▼158.1ppvs FY2024

Operating margin (FY2025)-4,498.06%▲2289.3ppvs FY2024

ROE (TTM to Jun 2026)N/A

Analyst consensus

RatingBuy

Target price$7.50▲68.73%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Actuals vs estimates by quarter, or any quarter against the same one a year earlier.

Next report

Nov 6, 2026

Q3 FY26 · EPS est -$0.24 · Revenue est $1.3M

Q2 FY26

Reported Aug 6, 2026 · Latest

HoverTap a quarter to inspect

Actual

-$0.24

Beat by 6.7%

Estimate

-$0.26

Street consensus

Year over year

n/m

vs Q2 FY25 · -$0.41

Vs prior quarter

n/m

vs Q1 FY26 · -$0.28

Price range $2.70-$3.96 · daily closes Apr 1-Jun 30

2 beats · 2 misses in the last 4 quarters

ActualEstimateBeatMissIn lineSame quarter last year

Institutional Sentiment

Prime Medicine, Inc. · PRME

From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.